Abstract: The present invention provides a cDNA of DOCK180 gene, which has a nucleotide sequence of SEQ ID No: 1 and of which translation product binds to the proto-oncogene product CRK, a recombinant vector containing this cDNA, a DOCK180 protein expressed from the cDNA which has a amino acid sequence of SEQ ID No: 2, and an antibody to the DOCK180 protein. According to the present invention, It is possible to develop new diagnosing and therapeutic techniques using DOCK180 protein and antibody against the protein.
Type:
Grant
Filed:
November 17, 1997
Date of Patent:
July 28, 1998
Assignee:
Research Development Corporation of Japan
Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptor, an isolated protein which is a human 5-HT.sub.1E receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1E receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1E receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1E receptor, pharmaceutical compounds related to human 5-HT.sub.1E receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1E receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1E receptor.
Type:
Grant
Filed:
October 12, 1995
Date of Patent:
July 28, 1998
Assignee:
Synaptic Pharmaceutical Corporation
Inventors:
Richard L. Weinshank, Theresa Branchek, Paul R. Hartig
Abstract: This application describes a high throughput assay for screening for compounds capable of binding to a fusion protein which consists of a target protein and an FK506-binding protein. The method for preparing the DNA encoding for the fusion protein and for expressing that DNA is also described in the application. The invention also discloses the recombinant DNA and protein sequences for several fusion proteins.
Type:
Grant
Filed:
September 4, 1996
Date of Patent:
July 21, 1998
Assignee:
Merck & Co., Inc.
Inventors:
Alice Marcy, Scott P. Salowe, Douglas Wisniewski
Abstract: A transfer port system between two sterile environments having docked and undocked positions which is made up of two door frames connected to the environments and two doors connected to the two door frames. When the sterile environments are in the docked position the door frames of the two doors are juxtaposed and in close physical contact with one another and when the two sterile environments are in the undocked position the two door frames are spaced apart from one another and the two doors seal the sterile environments. The two door frames and the doors have a potentially non-sterile peripheral juncture located at the juncture between the doors and door frames when the doors are in a closed position sealing the sterile environments when the sterile environments are in their docked position.
Abstract: A DNA fragment encoding a novel human-derived tumor cell growth inhibitor can be obtained from a cDNA library originating from human colon tumor cell, using as a DNA probe a DNA fragment encoding mouse human-derived tumor cell growth inhibitor. An expression plasmid bearing a promoter originating from Bacillus brevis, a signal peptide originating from Bacillus brevis and a DNA fragment encoding human-derived tumor cell growth inhibitor downstream of the signal peptide is constructed and Bacillus brevis is transformed by the expression plasmid. The resulting transformant is incubated to secret the novel inhibitor out of the cell so that the novel inhibitor can be produced efficiently.
Abstract: The present invention includes non-RGD cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. The inventive peptides are between five to about thirty amino acids in length and include the sequence (SEQ ID NO:8), Arg-Cys-Asp-Gly-X.sub.i where X.sub.i is any amino acid, and a five-membered cyclic portion. These non-RGD peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as cancer, osteoporosis, restenosis, and angiogenic-based diseases.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 14, 1998
Assignee:
IXSYS, Incorporated
Inventors:
Michael A. Palladino, Bruce A. Lee, William D. Huse, Judith A. Varner
Abstract: A method in which a temperature gradient is generated across a "gradient" block, and an apparatus comprising a block across which a temperature gradient can be generated. By setting up such a gradient, multiple reaction mixtures held in wells on the gradient block can be simultaneously run at temperatures which differ only slightly, thereby permitting an optimum temperature for the reaction to be quickly identified. In a preferred embodiment the gradient block is integrated into a thermal cycler used for nucleic acid amplification reactions.
Type:
Grant
Filed:
April 19, 1996
Date of Patent:
July 14, 1998
Assignee:
Stratagene
Inventors:
John Lewis Danssaert, Robert James Shopes, Daniel Davis Shoemaker
Abstract: A human Small CCN-Like Growth Factor polypeptide (SCGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonist against such polypeptides and their use as a therapeutic to treat atherosclerosis, tumors and scarring are also disclosed. Diagnostic assays for identifying mutations in SCGF nucleic acid sequences and altered levels of the SCGF polypeptide are also disclosed.
Abstract: A human receptor protein which binds to the human immunodeficiency virus (HIV) viral protein R (vpr) is disclosed. Pharmaceutical compositions that comprise the receptor protein, compositions useful to produce the receptor protein and methods of making and using the receptor protein are disclosed.
Type:
Grant
Filed:
October 24, 1996
Date of Patent:
July 14, 1998
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
David B. Weiner, David Nathan Levy, Yosef Refaeli
Abstract: The present invention relates to a growth factor preparation derived from a mixed lymphocyte culture, and a process for its production. The invention also relates to a cell culture medium containing said growth factor preparation. The invention further relates to a process for culturing plasma cells and producing antibodies by using said cell culture medium.
Type:
Grant
Filed:
December 10, 1996
Date of Patent:
July 7, 1998
Inventors:
Olavi Kajander, Ilpo Kuronen, Kaarina Tikkanen
Abstract: Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.
Type:
Grant
Filed:
March 11, 1996
Date of Patent:
July 7, 1998
Assignee:
Allergan, Inc.
Inventors:
Elliott S. Klein, Sunil Nagpal, Roshantha A. Chandraratna
Abstract: Chronic fatigue syndrome in an individual is diagnosed by determining the level of RNase L inhibitor mRNA or protein in peripheral blood mononuclear cells. Significantly decreased levels of RLI mRNA or protein compared to healthy control individuals indicates the presence of chronic fatigue syndrome.
Abstract: The present invention is directed to methods of detecting angiostatin protein which is an endothelial cell inhibitor. The angiostatin protein is a protein isolated from blood or urine that is eluted as single peak from C4-reverse phase high performance liquid chromatography. One method of the present invention includes combining a sample suspected of containing angiostatin protein with an antibody which is specific for angiostatin protein. Another method of the present invention includes isolating the protein and detecting the presence of angiostatin protein by performing an endothelial cell proliferation inhibiting assay.
Abstract: A new endothelin B receptor has been identified, and the amino acid and nucleotide sequence of the receptor are provided. The nucleotide sequence is useful to construct expression cassettes and vectors to produce host cells which are capable of expressing the receptor, its mutants, fragments, or fusions. Such polypeptides are useful for identifying new endothelin agonists and antagonists.
Abstract: In an apparatus for the irradiation of body fluids by ultraviolet light in a containment for receiving the body fluids which is disposed in the radiation range of an ultraviolet light source, the containment includes baffle means arranged so as to subject the body fluids circulated through the containment to turbulence whereby the body fluid in the containment is uniformly exposed to the UV radiation.
Abstract: The present invention provides a novel polypeptide, Connective Tissue Growth Factor (CTGF), polynucleotides encoding CTGF, and including 5' and 3' untranslated nucleotides, antibodies reactive with CTGF and means for producing CTGF. Also provided are diagnostic and therapeutic methods for using CTGF, as well as an assay for identifying compositions which affect the expression of CTGF polynucleotide. The invention provides a novel TGF-.beta. responsive element upstream of the polynucleotide encoding CTGF structural gene.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
June 23, 1998
Assignee:
University of South Florida
Inventors:
Gary R. Grotendorst, Douglass M. Bradham, Jr.
Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.